Strobl M, Gallaher J, Robertson-Tessi M, West J, Anderson A
Ann Oncol. 2023; 34(10):867-884.
PMID: 37777307
PMC: 10688269.
DOI: 10.1016/j.annonc.2023.08.008.
Gregory C
Immunol Rev. 2023; 319(1):100-127.
PMID: 37553811
PMC: 10952466.
DOI: 10.1111/imr.13259.
Strobl M, Gallaher J, West J, Robertson-Tessi M, Maini P, Anderson A
Commun Med (Lond). 2022; 2:46.
PMID: 35603284
PMC: 9053239.
DOI: 10.1038/s43856-022-00110-x.
Kasperski A
Int J Mol Sci. 2022; 23(7).
PMID: 35409376
PMC: 8999494.
DOI: 10.3390/ijms23074017.
Tribukait B
Cancers (Basel). 2021; 13(21).
PMID: 34771604
PMC: 8582392.
DOI: 10.3390/cancers13215442.
Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
Strobl M, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown J
Cancer Res. 2020; 81(4):1135-1147.
PMID: 33172930
PMC: 8455086.
DOI: 10.1158/0008-5472.CAN-20-0806.
The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer.
Jeong J, Taasti V, Jackson A, Deasy J
Radiother Oncol. 2020; 153:265-271.
PMID: 32976878
PMC: 7770609.
DOI: 10.1016/j.radonc.2020.09.027.
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.
Messerschmidt J, Bhattacharya P, Messerschmidt G
Curr Oncol Rep. 2017; 19(10):66.
PMID: 28803390
DOI: 10.1007/s11912-017-0625-2.
Cancer heterogeneity is not compatible with one unique cancer cell metabolic map.
Strickaert A, Saiselet M, Dom G, De Deken X, Dumont J, Feron O
Oncogene. 2016; 36(19):2637-2642.
PMID: 27797377
PMC: 5442421.
DOI: 10.1038/onc.2016.411.
An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.
Miranda Cona M, de Witte P, Verbruggen A, Ni Y
World J Methodol. 2014; 3(4):45-64.
PMID: 25237623
PMC: 4145570.
DOI: 10.5662/wjm.v3.i4.45.
Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property?.
Antoniou A, Hebrant A, Dom G, Dumont J, Maenhaut C
Cell Cycle. 2013; 12(24):3743-8.
PMID: 24270846
PMC: 3905066.
DOI: 10.4161/cc.27305.
TrAp: a tree approach for fingerprinting subclonal tumor composition.
Strino F, Parisi F, Micsinai M, Kluger Y
Nucleic Acids Res. 2013; 41(17):e165.
PMID: 23892400
PMC: 3783191.
DOI: 10.1093/nar/gkt641.
Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response.
Jeong J, Shoghi K, Deasy J
Phys Med Biol. 2013; 58(14):4897-919.
PMID: 23787766
PMC: 4784425.
DOI: 10.1088/0031-9155/58/14/4897.
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence".
Tarabichi M, Antoniou A, Saiselet M, Pita J, Andry G, Dumont J
Cancer Metastasis Rev. 2013; 32(3-4):403-21.
PMID: 23615877
PMC: 3843370.
DOI: 10.1007/s10555-013-9431-y.
F-18 FDG PET/CT and Tc-99m sulfur colloid SPECT imaging in the diagnosis and treatment of a case of dual solitary fibrous tumors of the retroperitoneum and pancreas.
Azadi J, Subhawong A, Durand D
J Radiol Case Rep. 2012; 6(3):32-7.
PMID: 22690289
PMC: 3370710.
DOI: 10.3941/jrcr.v6i3.904.
Clonal evolution in cancer.
Greaves M, Maley C
Nature. 2012; 481(7381):306-13.
PMID: 22258609
PMC: 3367003.
DOI: 10.1038/nature10762.
A comparative study of cell proliferation markers in breast carcinomas.
Leong A, Vinyuvat S, Suthipintawong C, Milios J
Clin Mol Pathol. 1995; 48(2):M83-7.
PMID: 16695987
PMC: 407930.
DOI: 10.1136/mp.48.2.m83.
Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas.
Blomqvist C, Huuhtanen R, Pan Y, Wiklund T, Tarkkanen M, Virolainen M
Br J Cancer. 1996; 73(12):1556-9.
PMID: 8664129
PMC: 2074548.
DOI: 10.1038/bjc.1996.293.
Chemotherapeutic drug resistance in the management of head and neck cancer.
Bier H
Eur Arch Otorhinolaryngol. 1993; 250(4):200-8.
PMID: 8369114
DOI: 10.1007/BF00171524.
Which proliferation markers for routine immunohistology? A comparison of five antibodies.
Rose D, Maddox P, Brown D
J Clin Pathol. 1994; 47(11):1010-4.
PMID: 7829674
PMC: 503063.
DOI: 10.1136/jcp.47.11.1010.
